Rapport Therapeutics, Inc. RAPP Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $20M— | —— | —— | —— | $0— | ||
| $32.72M+8.1% | $30.26M+35.8% | $22.28M-1.8% | $22.68M+15.9% | $19.57M+13.8% | ||
| $11.5M— | —— | —— | —— | $7.54M— | ||
| $44.22M+14.8% | $38.51M+28.4% | $29.99M+1.7% | $29.5M+8.8% | $27.11M+15.3% | ||
| $44.22M+14.8% | $38.51M+28.4% | $29.99M+1.7% | $29.5M+8.8% | $27.11M+15.3% | ||
| -$24.22M+37.1% | -$38.51M-28.4% | -$29.99M-1.7% | -$29.5M-8.8% | -$27.11M-15.3% | ||
| -121.1%— | —— | —— | —— | —— | ||
| $4.36M-8.2% | $4.75M+55.0% | $3.06M+10.7% | $2.76M-9.2% | $3.05M-14.0% | ||
| $4.36M-8.2% | $4.75M+55.0% | $3.06M+10.7% | $2.76M-9.2% | $3.05M-14.0% | ||
| -$19.86M+41.2% | -$33.76M-25.4% | -$26.93M-0.7% | -$26.73M-11.1% | -$24.06M-20.4% | ||
| -99.3%— | —— | —— | —— | —— | ||
| -$0.42+40.8% | -$0.710.0% | -$0.71+5.3% | -$0.75-10.3% | -$0.68-467% | ||
| -$0.42+40.8% | -$0.710.0% | -$0.71+5.3% | -$0.75-10.3% | -$0.68-467% | ||
| 47.2M+21.3% | 38.9M+2.6% | 37.9M+7.0% | 35.4M+0.5% | 35.3M+70.1% | ||
| 47.2M+21.3% | 38.9M+2.6% | 37.9M+7.0% | 35.4M+0.5% | 35.3M+70.1% | ||
| -$20.91M+37.3% | -$33.36M-24.9% | -$26.7M0.0% | -$26.71M-13.0% | -$23.64M-13.1% | ||
| -$1.05M-362% | $401K+81.4% | $221K+1,063% | $19K-95.6% | $427K+146% | ||
| $20M— | —— | —— | —— | $0— | ||
| -$24.22M+37.1% | -$38.51M-28.4% | -$29.99M-1.7% | -$29.5M-8.8% | -$27.11M-15.3% | ||
| -$23.99M+37.3% | -$38.24M-28.6% | -$29.73M-1.7% | -$29.24M-8.9% | -$26.86M-15.5% | ||
| -$23.99M+37.3% | -$38.24M-28.6% | -$29.73M-1.7% | -$29.24M-8.9% | -$26.86M-15.5% | ||
| -119.9%— | —— | —— | —— | —— | ||
| -$24.22M+37.1% | -$38.51M-28.4% | -$29.99M-1.7% | -$29.5M-8.8% | -$27.11M-15.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Rapport Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.